OraSure Technologies (NASDAQ:OSUR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.
According to Zacks, “OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. “
A number of other research firms have also commented on OSUR. Jefferies Group reaffirmed a “buy” rating and set a $20.00 price target on shares of OraSure Technologies in a research report on Tuesday, September 12th. Canaccord Genuity reiterated a “buy” rating and set a $22.00 target price on shares of OraSure Technologies in a report on Tuesday, September 19th. BidaskClub upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a report on Thursday, December 21st. Finally, ValuEngine downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. OraSure Technologies currently has a consensus rating of “Buy” and a consensus target price of $19.65.
OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 EPS for the quarter, meeting analysts’ consensus estimates of $0.09. The business had revenue of $42.30 million during the quarter, compared to analyst estimates of $40.87 million. OraSure Technologies had a return on equity of 14.12% and a net margin of 20.48%. OraSure Technologies’s quarterly revenue was up 31.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.11 EPS. equities analysts predict that OraSure Technologies will post 0.43 earnings per share for the current year.
In other news, Director Mara G. Aspinall bought 5,000 shares of OraSure Technologies stock in a transaction on Tuesday, November 7th. The shares were purchased at an average price of $14.23 per share, for a total transaction of $71,150.00. Following the acquisition, the director now owns 5,000 shares of the company’s stock, valued at $71,150. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 6.40% of the stock is currently owned by corporate insiders.
Several hedge funds have recently bought and sold shares of the business. Profund Advisors LLC grew its holdings in shares of OraSure Technologies by 2.8% during the 2nd quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock worth $188,000 after acquiring an additional 293 shares during the period. Victory Capital Management Inc. grew its holdings in shares of OraSure Technologies by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 9,070 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 1,360 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of OraSure Technologies by 3.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 44,672 shares of the medical instruments supplier’s stock worth $772,000 after acquiring an additional 1,573 shares during the period. Rhumbline Advisers grew its holdings in shares of OraSure Technologies by 2.3% during the 2nd quarter. Rhumbline Advisers now owns 106,594 shares of the medical instruments supplier’s stock worth $1,840,000 after acquiring an additional 2,428 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in shares of OraSure Technologies by 0.7% during the 3rd quarter. Principal Financial Group Inc. now owns 482,574 shares of the medical instruments supplier’s stock worth $10,858,000 after acquiring an additional 3,531 shares during the period. Hedge funds and other institutional investors own 94.43% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.com-unik.info/2018/01/09/orasure-technologies-osur-upgraded-to-hold-by-zacks-investment-research.html.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.